|
Frank [25]
|
Survival (Nomogram presented)
|
Biopsy gleason score, clinical stage, EBRT, pre-treatment PSA,
|
Yes
|
External validation of Prostogram
|
0.49; 95% CI 0.37–0.61
|
c-index
|
208 (15)
|
5 year BFFF
|
Brachytherapy
|
|
Kaplan [12]
|
Survival (Nomogram presented)
|
Kattan’s: Pretreatment PSA level, Gleason score, clinical stage, adjuvant EBRT
|
Yes
|
External validation of Kattan
|
0.51
|
c-index
|
747 (31)
|
BFFF
|
125 iodine brachytherapy
|
|
Frank [47]
|
Survival (Nomogram presented)
|
Pretreatment PSA level, Gleason sum score, T stage, and EBRT
|
Yes
|
External validation of Prostogram
|
0.66
|
c-index
|
683 (29)
|
BCF
|
Brachytherapy
|
|
Zelefsky [10]
|
Proportional hazards regression (Nomogram presented)
|
Clinical stage, Gleason, pretreatment PSA
|
Yes
|
Not stated
|
0.70
|
c-index
|
1466 (NR)
|
BCF
|
Brachytherapy
|
|
Potters [16]
|
Survival (Cox,Nomogram presented)
|
Clinical stage, Biopsy Gleason sum, Isotope used, EBRT, D90, pretreatment PSA
|
No, includes isotope used, D90
|
Internal (bootstrapping)
|
0.71
|
c-index
|
5931 (NR)
|
9-year BFFF
|
Brachytherapy
|
|
D’Amico [42]
|
Survival Model (Fine and Gray)
|
Year of brachytherapy, Log (PSA)per unit increase, Gleason score, Age
|
Yes
|
Not stated
|
Not stated
|
NA
|
221 (32)
|
PCSM and presence of hormone-refractory metastatic prostate cancer
|
Brachytherapy
|
|
Sylvester [57]
|
Survival model (Cox)
|
PSA only (<10, 10.1–19.9, >20)
|
Yes
|
Not stated
|
Not stated
|
NA
|
215 (NR)
|
15 year BFFF
|
Brachytherapy
|
|
Sylvester [57]
|
Survival model (Cox)
|
PSA only (<10, 10.1–19.9, >20)
|
Yes
|
Not stated
|
Not stated
|
NA
|
215 (NR)
|
15 year PCSM
|
Brachytherapy
|
|
Sylvester [57]
|
Survival model (Cox)
|
PSA only (<10, 10.1–19.9, >20)
|
Yes
|
Not stated
|
Not stated
|
NA
|
215 (NR)
|
15 year OS.
|
Brachytherapy
|
|
Bittner [27]
|
Survival model (Cox)
|
Number of biopsy cores, PSA, Gleason score, % positive biopsies, V100, EBRT, Risk group, hypertension, Tobacco use, perineural invasion
|
No, tobacco use, V100, hypertension included.
|
Not stated
|
Not stated
|
NA
|
1613 (NR)
|
BFFF
|
Brachytherapy
|
|
Bittner [27]
|
Survival model (Cox)
|
PSA, Gleason score, % positive biopsies, EBRT, Risk group, hypertension
|
No, hypertension
|
Not stated
|
Not stated
|
NA
|
1613 (NR)
|
PCSM
|
Brachytherapy
|
|
Bittner [27]
|
Survival model (Cox)
|
Number of biopsy cores, age at implant, BMI, V100, D90, EBRT, Risk group, hypertension, diabetes, Tobacco use
|
No, BMI, V100, D90, hypertension, diabetes included
|
Not stated
|
Not stated
|
NA
|
1613 (NR)
|
OS
|
Brachytherapy
|
|
Cooperberg [39]
|
Survival model (Cox)
|
CAPRA scores (based on PSA, Biopsy Gleason, Age at diagnosis, clinical tumour stage and % biopsy cores positive for cancer)
|
Yes
|
Not stated
|
Not stated
|
NA
|
1441 (17)
|
PCSM
|
Brachytherapy
|
|
Yoshida [15]
|
Survival model
|
PRIX score derived from PSA, Gleason and clinical stage
|
Yes
|
External
|
Not stated
|
NA
|
100 (9)
|
5 year BCF
|
HDR-ISBT
|
|
Yoshida [15]
|
Survival model
|
PRIX score derived from PSA, Gleason and clinical stage
|
Yes
|
External
|
Not stated
|
NA
|
100 (9)
|
5 year OS
|
HDR-ISBT
|
|
Marshall [11]
|
Survival model (Cox)
|
Age, Risk group, hormone treatment, Total BED
|
Yes
|
Not stated
|
Not stated
|
NA
|
2495 (251)
|
BCF
|
Brachytherapy
|
